- Home
- SD vs BBNX Comparison
SD vs BBNX Comparison
Compare SD & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | BBNX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 493.1M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | SD | BBNX |
|---|---|---|
| Price | $13.39 | $16.80 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $15.00 | ★ $23.80 |
| AVG Volume (30 Days) | 334.4K | ★ 996.1K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | $34.90 |
| Revenue Next Year | $1.75 | $34.63 |
| P/E Ratio | $26.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $8.80 |
| 52 Week High | $18.45 | $32.71 |
Technical Indicators
Market Signals| Indicator | SD | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 64.22 |
| Support Level | $13.26 | $16.02 |
| Resistance Level | $15.80 | $32.52 |
| Average True Range (ATR) | 0.36 | 1.03 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.87 | 83.96 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.